Form 4: Armata Pharmaceuticals Director Odysseas Kostas D Acquires Stock Options

Director Odysseas Kostas D reports acquisition of stock options in Armata Pharmaceuticals.

Summary

• On March 14, 2024, Odysseas Kostas D, a director of Armata Pharmaceuticals, acquired stock options.
• The first set of options, for 39,666 shares, vests upon the company's 2024 annual shareholders meeting, contingent on continuous service.
• The second set of options, for 54,343 shares, vests in two tranches: 50% on March 14, 2025, and 50% on March 14, 2026, also subject to continuous service.
• The exercise price for both sets of options is $3.38.
• Following the transaction, Odysseas Kostas D directly owns 94,009 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of options by a director is generally viewed as a positive, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continuous service, suggesting an expectation of continued involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment, as it aligns the director's interests with the company's success.

Next Steps

• The options for 39,666 shares will vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting.
• The options for 54,343 shares will vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date.

Key Dates